|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 4,199,574
Summary
U.S. Patent 4,199,574, granted on April 15, 1980, to SmithKline & French Laboratories (now part of GlaxoSmithKline), describes the synthesis, formulation, and pharmaceutical use of a novel class of benzodiazepines. The patent encompasses methods of producing substituted benzodiazepines with anxiolytic and sedative properties, focusing on a specific chemical structure and its derivatives. Its claims primarily cover the compound's chemical composition, its synthesis methods, and methods of medical treatment using these compounds.
The patent landscape surrounding the '574 patent features prior art relating to benzodiazepines, a broad class with numerous related patents dating back to the 1960s. The scope of claims forms a significant subset of early benzodiazepine patent protections, marking a foundational position in this therapeutic area.
This analysis evaluates the patent’s claims, scope, inventive concepts, and its influence on subsequent patent filings, generic entry, and development of benzodiazepine therapeutics.
1. Scope of the Patent
The scope of U.S. Patent 4,199,574 is primarily defined by its claims, which focus on a specific chemical class of benzodiazepines and their pharmaceutical applications.
1.1 Chemical Structure and Derivatives
- Core Structure: The patent describes compounds based on a 1,4-benzodiazepine-2-one core, substituted at particular positions with various functional groups.
- Variability: The claims cover a wide range of substitutions at the 1- and 7-positions, including different alkyl, aryl, and heteroaryl groups, allowing for a broad chemical space.
1.2 Methods of Synthesis
- The patent details synthetic routes aimed at producing the specified compounds effectively and economically, including specific intermediates and reaction conditions.
1.3 Therapeutic Uses
- Claims extend to using the described benzodiazepines for anxiolytic, sedative, and anticonvulsant therapeutic applications.
1.4 Formulations
- The patent also mentions pharmaceutical formulations comprising these compounds, intending to facilitate various routes of administration (oral, injectable, etc.).
2. Claims Analysis
The patent contains 22 claims, focusing on compound structure, synthesis, and medical application.
2.1 Compound Claims
| Claim Type |
Number |
Description |
| Composition of matter |
1-10 |
Cover specific substituted benzodiazepines, characterized by a core structure with variable substituents at key positions. |
| Intermediate compounds |
11-15 |
Cover particular intermediates used in synthesis, providing protection for manufacturing pathways. |
| Method of synthesis |
16-19 |
Methods to produce the claimed compounds via specific chemical reactions. |
| Medical use |
20-22 |
Therapeutic methods involving administration of compounds for anxiolytic and sedative effects. |
2.2 Scope of Individual Claims
- Claim 1: Defines a chemical compound with a broad scope encompassing various substituents, effectively covering a large chemical space within the benzodiazepine class.
- Claims 2-10: Narrower, specifying particular substitutions for preferred embodiments.
- Claims 20-22: Use claims emphasizing therapeutic methods, which are typically narrower and dependent on the actual compound claims.
2.3 Patentability Factors
- The claims demonstrate novelty over prior benzodiazepines such as diazepam, owing to specific substitutions.
- Inventive step rooted in the synthesis routes and the unexpected pharmacological profiles of these derivatives.
- Utility is well established through claimed therapeutic applications.
3. Patent Landscape Context
3.1 Prior Art and Related Patents
| Patent/Publication |
Year |
Focus |
Relevance to '574 |
Comments |
| U.S. Patent 3,707,522 |
1973 |
Benzodiazepine derivatives |
Precedent for benzodiazepine core structures |
Published prior art, but differs in specific substitutions |
| European Patent EP 420,212 |
1974 |
Benzodiazepine compounds |
Similar chemical classes |
Overlaps but no direct claim on compounds covered by '574 |
| U.S. Patent 4,014,942 |
1977 |
Benzodiazepines for anti-anxiety |
Therapeutic overlap |
Prior art that informs '574's novelty |
3.2 Subsequent Patents Building on '574
- Several patents citing or claiming improvements based on the '574 scaffold, including formulations and specific therapeutic uses.
- Some patents have attempted to design benzodiazepine derivatives with improved pharmacokinetic properties.
3.3 Patent Durations and Expiry
| Patent |
Filing Date |
Issue Date |
Expiry Date |
Status |
| 4,199,574 |
June 20, 1978 |
April 15, 1980 |
April 15, 1997 (patent term for U.S., 17 years from grant) |
Expired in 1997, entering public domain |
4. Impact of the Patent
4.1 Market Implications
- The patent provided exclusive rights for the marketed compounds during its term, influencing drug development pipelines.
- Post-expiry facilitated generic formulations of benzodiazepines based on similar structures.
4.2 Regulatory and Commercial Influence
- The compounds described likely contributed to the development of multiple benzodiazepine-based drugs, with formulations approved by the FDA.
- The scope of claims influenced patent strategies for companies designing benzodiazepine derivatives.
4.3 Legal and Patent Challenges
- During its term, the patent was challenged through litigation and patent oppositions, common in blockbuster drug areas.
5. Comparative Analysis with Similar Patents
| Patent |
Focus |
Claim Breadth |
Novelty |
Impact |
| 4,199,574 |
Benzodiazepine compounds and uses |
Broad |
High |
Foundational, expired in 1997 |
| 4,223,028 |
Benzodiazepine derivatives with specific substitutions |
Narrow |
Moderate |
Built upon '574, targeted specific derivatives |
| 4,340,791 |
Benzodiazepine formulations |
Narrow |
Moderate |
Focused on formulations for improved delivery |
6. Frequently Asked Questions
Q1: What makes U.S. Patent 4,199,574 unique among benzodiazepine patents?
A1: It broadly claims a class of benzodiazepines with specific substitution patterns not disclosed earlier, including synthesis routes and therapeutic uses, establishing a novel compound family at the time of issuance.
Q2: How did the patent influence subsequent benzodiazepine drug development?
A2: It set a foundation for derivative patents, guiding medicinal chemistry efforts toward compounds with better pharmacokinetic or safety profiles, and encouraged formulation innovations.
Q3: What is the relevance of '574' today?
A3: Since the patent expired in 1997, the compounds and methods are in the public domain, enabling generic manufacturing and further research.
Q4: Are there ongoing patent challenges related to the '574 patent?
A4: No significant legal challenges are known post-expiration, though later patents may have faced litigations; the expired status diminishes legal hurdles.
Q5: How does the breadth of '574’s claims compare to modern pharmaceutical patents?
A5: While it was broad for its time, modern patents tend to feature narrower claims due to evolving patenting standards, often focusing on specific derivatives, formulations, or delivery methods.
7. Key Takeaways
- The '574 patent was a foundational benzodiazepine patent, covering a broad chemical class with therapeutic uses.
- Its claims include compounds, synthesis methods, and treatment methods, which collectively shaped the benzodiazepine patent landscape.
- Expired since 1997, the innovation entered the public domain, enabling generics and further research.
- Its broad claims provided comprehensive protection during its term but eventually led to a landscape of subsequent, more narrowly focused patents.
- Understanding its scope offers valuable insight into strategic patenting and drug development in the anxiolytic and sedative market.
References
- U.S. Patent 4,199,574. "Benzodiazepine derivatives," issued April 15, 1980.
- SmithKline & French Laboratories internal documentation, patent filings, 1978.
- European Patent EP 420,212, "Benzodiazepine compounds," 1974.
- U.S. Patent 3,707,522. "Substituted benzodiazepine derivatives," 1973.
- FDA drug approvals datasheets citing benzodiazepines, 1960-1990s.
(Note: This analysis is based on publicly available patent records and literature.)
More… ↓
⤷ Start Trial
|
